Niraparib for the treatment of metastatic ccRCC in a patient with CDK12 and RAD51C mutations: a case report
Xiaolong Yue,
Chenkang Yang,
Dandan Cao
et al.
Abstract:BackgroundNiraparib, a poly ADP-ribose polymerase inhibitors (PARPi), has been widely applied in the intervention of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nevertheless, as of the present moment, there are limited instances demonstrating favorable outcomes stemming from niraparib therapy in patients with clear cell renal cell carcinoma (ccRCC).Case presentationHere, we report a case of a 50-year-old patient with ccRCC who subsequently developed distant metastasis. The patient receive… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.